Dublin, Jan. 04, 2023 (GLOBE NEWSWIRE) -- The "Global T-Cell Therapy Market - Distribution by Type of Therapy, Target Indications, Target Antigens, Key Players and Key Geographies: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
This report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies. The report highlights the efforts of several stakeholders engaged in this rapidly evolving segment of the biopharmaceutical industry.
Cancer is known to be one of the leading causes of deaths worldwide. In fact, as per the WHO, close to 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cancer cases will be added to the global numbers, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities and national health systems.
Although there are several treatment options available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is difficult to achieve. In this context, immunotherapies, a relatively recent addition to the gamut of anticancer interventions, have demonstrated significant promise.
Amidst the current initiatives undertaken to develop more targeted anti-cancer therapies, T-cell therapies (specifically CAR-T therapies, TCR therapies and TIL therapies) have emerged as a promising option, owing to their ability to eradicate tumor cells from the body with minimal treatment-related side effects.
Overall, this highly specific and promising form of T-cell therapy treatment, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry.
A number of chimeric antigen receptor T-cell (CAR-T) therapies have so far been evaluated and approved for several hematological malignancies, including KYMRIAH (Novartis), YESCARTA (Gilead Sciences), TECARTUST (Gilead Sciences), Breyanzi (Bristol Myers Squibb), AbecmaT (Bristol Myers Squibb) and CARVYKTIT (Janssen Biotech / Legend Biotech). It is worth mentioning that, recently, KIMMTRAK (Immunocore) became the first T-cell receptor (TCR) therapy to receive approval from the USFDA.
Presently, more than 250 companies are engaged in the development of more than 1,200 early and late-stage T-cell therapies, worldwide. Several promising leads are anticipated to be commercially launched over the coming decade, following which the market is projected to grow at a substantial pace.
Over 6,800 patents related to CAR-T therapies, TCR therapies and TIL therapies have been recently filed / granted, demonstrating the continued innovation in this domain. In addition, close to 440 collaborations have been inked between industry / academic stakeholders to advance the development of various pipeline candidates.
Moreover, to fund product development initiatives in this domain, capital investments worth USD 30 billion have been made by various private and public sector investors in the last few years. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the T-cell immunotherapy market is anticipated to witness substantial growth in the mid to long-term.
Key Questions Answered
- What are the prevalent R&D trends related to T-cell immunotherapies (specifically CAR-Ts, TCRs and TILs)?
- What kind of clinical conditions can be treated using T-cell immunotherapies?
- Who are the leading industry and non-industry players in this market?
- In which geographies extensive research on T-cell immunotherapy is being conducted?
- What kind of partnership models are commonly adopted by industry stakeholders?
- Who are the key investors in T-cell immunotherapy domain?
- Who are the key opinion leaders / experts from renowned academic and research institutes who can help drive product development efforts in this domain?
- How is the intellectual property landscape for global T-cell therapies likely to evolve in the foreseen future?
- Who are the key service providers (CMOs / CDMOs) with capabilities to develop and manufacture T-cell therapies?
- What are the key factors that are likely to influence the evolution of the T-cell immunotherapies market?
- How is the current and future market opportunity likely to be distributed across key market segments?
- What are the key promotional strategies used by companies having marketed products?
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. CAR-T CELL THERAPIES: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. CAR-T Cell Therapies: Overall Market Landscape
4.3. CAR-T Cell Therapies: Overall Developer Landscape
5. TCR-BASED THERAPIES: MARKET LANDSCAPE
5.1. Chapter Overview
5.2. TCR-based Therapies: Overall Market Landscape
5.3. TCR-based Therapies: Overall Developer Landscape
6. TIL-BASED THERAPIES: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. TIL-based Therapies: Overall Market Landscape
6.2.1. Analysis by Type of Developer
6.2.2. Analysis by Phase of Development
6.2.3. Analysis by Therapeutic Area
6.2.4. Analysis by Key Target Indication
6.2.5. Analysis by Source of T-Cells
6.2.6. Analysis by Route of Administration
6.2.7. Analysis by Dosing Frequency
6.2.8. Analysis by Target Patient Segment
6.2.9. Analysis by Type of Therapy
6.2.10. Most Active Industry Players: Analysis by Number of TIL-based Therapies
6.2.11. Most Active Non-Industry Players: Analysis by Number of TIL-based Therapies
6.3. TIL-based Therapies: Overall Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
7. KEY INSIGHTS
7.1. Chapter Overview
7.2. T-Cell Immunotherapies: Competitive Analysis by Popular Target Antigen
7.2.1. Popular Targets Related to Hematological Malignancies
7.2.2. Popular Targets Related to Solid Tumors
7.3. T-Cell Immunotherapies: CAR Construct Analysis
7.3.1. Analysis by Generation of CAR
7.3.2. Analysis by Type of scFv Antibody
7.3.3. Analysis by Type of Virus Used
7.3.4. Analysis by Type of Gene Transfer Method Used
7.3.5. Analysis by Co-Stimulatory Domain
8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. CAR-T Cell Therapies: Clinical Trial Analysis
8.4. TCR-based Therapies: Clinical Trial Analysis
8.5. TIL-based Therapies: Clinical Trial Analysis
9. KEY OPINION LEADERS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. CAR-T Cell Therapies: Key Opinion Leaders
9.5. TCR-based Therapies: Key Opinion Leaders
9.6. TIL-based Therapies: Key Opinion Leaders
10. CAR-T CELL THERAPY PROFILES
10.1. Chapter Overview
10.2. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
10.3. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
10.4. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
10.5. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
10.6. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
10.7. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
10.8. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
10.9. TBI-1501 / CD19 CAR-T Cell Therapy (Takara Bio)
10.10. AUTO1 / Obecabtagene Autoleucel / obe-cel (Autolus)
10.11. AUTO3 / CD19/22 CAR-T (Autolus)
11. TCR-BASED THERAPY PROFILES
11.1. Chapter Overview
11.2. Kimmtrak / IMCgp100 / Tebentafusp (Immunocore)
11.3. GSK3377794 / NY-ESO-1C259 T-Cells / Letetresgene Autoleucel (GlaxoSmithKline)
11.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
11.5. JTCR016 (Juno Therapeutics)
11.6. TBI-1301 (Takara Bio)
11.7. MDG1011 (Medigene)
12. TIL-BASED THERAPY PROFILES
12.1. Chapter Overview
12.2. LN-144 / Lifileucel (Iovance Biotherapeutics)
12.3. LN-145 (Iovance Biotherapeutics)
12.4. ITIL-168 (Instil Bio)
12.5. LTX-315 (Lytix Biopharma)
13. EMERGING TECHNOLOGIES
13.1. Chapter Overview
13.2. Genome Editing Technologies
13.3. Designing T-Cell Therapies with Improved Characteristics
13.4. Future Perspectives
14. PARTNERSHIPS AND COLLABORATIONS
15. FUNDING AND INVESTMENT ANALYSIS
15.1. Chapter Overview
15.2. Type of Funding
15.3. T-Cell Immunotherapy Market: Funding and Investment Analysis
16. PATENT ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology
16.3. Patent Analysis: Distribution by Type of Patent
16.4. CAR-T Cell Therapies: Patent Analysis
16.5. TCR- based Therapies
16.6. TIL- based Therapies
17. OTHER T-CELL IMMUNOTHERAPIES
17.1. Chapter Overview
17.2. Other T-Cell Immunotherapies
17.3. Other T-Cell Immunotherapies: Market Overview
17.4. Key Considerations for Developing T-Cell Immunotherapies
17.5. Concluding Remarks
18. CASE STUDY: CELL THERAPY MANUFACTURING
18.1. Chapter Overview
18.2. Overview of Cell Therapy Manufacturing
18.3. Cell Therapy Manufacturing Models
18.4. Scalability of Cell Therapy Manufacturing Processes
18.5. Types of Cell Therapy Manufacturers
18.6. Key Challenges Related to Manufacturing of Cell Therapies
18.7. Important Factors for Cell Therapy Manufacturing
18.8. Automation of Cell Therapy Manufacturing Process
18.9. Cell Therapy Manufacturing Supply Chain
18.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers
18.11. Regulatory Landscape
18.12. Future Perspectives
19. COST PRICE ANALYSIS
19.1. Chapter Overview
19.2. Factors Contributing to the High Price of Cell / Gene Therapies
19.3. Pricing Models for T-Cell Immunotherapies
19.3.1. Based on Associated Costs
19.3.2. Based on Availability of Competing Products
19.3.3. Based on Patient Segment
19.3.4. Based on Opinions of Industry Experts
19.4. Reimbursement related Considerations for T-Cell Immunotherapies
19.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T therapies
20. MARKET FORECAST AND OPPORTUNITY ANALYSIS
21. PROMOTIONAL ANALYSIS
22. COMPANY PROFILES
22.1. Chapter Overview
22.2. Adaptimmune Therapeutics
22.3. Alaunos Therapeutics
22.4. Autolus
22.5. bluebird Bio
22.6. Bristol Myers Squibb
22.7. Carsgen Therapeutics
22.8. Cellectis
22.9. Cellular Biomedicine Group
22.10. Gilead Sciences
22.11. GlaxoSmithKline
22.12. Immatics
22.13. Immunocore
22.14. Innovative Cellular Therapeutics
22.15. Iovance Biotherapeutics
22.16. Kuur Therapeutics
22.17. Lion TCR
22.18. Noile-Immune Biotech
22.19. Novartis
22.20. Shanghai GeneChem
22.21. Sinobioway Cell Therapy
22.22. Takara Bio
22.23. Wellington Zhaotai Therapies
22.24. Zelluna immunotherapy
23. CONCLUDING REMARKS
24. EXECUTIVE INSIGHTS
25. APPENDIX 1: TABULATED DATA
26. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/lmt9i1
